EasyChair Preprint

№ 13688

# The Role of High-Flow Nasal Oxygen Therapy in Preventing Intubation in COVID-19 Patients with Acute Respiratory Failure

Abill Robert



June 17, 2024

# The Role of High-Flow Nasal Oxygen Therapy in Preventing Intubation in COVID-19 Patients with Acute Respiratory Failure

**Author**

**Abill Robert**

**Date: June 16, 2024**

## Abstract

The COVID-19 pandemic has presented unprecedented challenges to healthcare systems worldwide, particularly in the management of acute respiratory failure (ARF). High-flow nasal oxygen (HFNO) therapy has emerged as a pivotal non-invasive respiratory support modality that may prevent the need for intubation in COVID-19 patients experiencing ARF. This study aims to explore the efficacy, safety, and clinical outcomes associated with HFNO therapy in this patient population. By delivering heated, humidified oxygen at high flow rates, HFNO can improve oxygenation, reduce work of breathing, and maintain mucociliary function. We conducted a comprehensive review of recent clinical trials and observational studies to evaluate the impact of HFNO on intubation rates, patient survival, and overall respiratory function. Our findings indicate that HFNO therapy significantly decreases the necessity for mechanical ventilation, thereby reducing the associated risks and complications. Additionally, HFNO has demonstrated a favorable safety profile, with fewer adverse events compared to other non-invasive ventilation methods. However, the success of HFNO therapy is contingent upon careful patient selection and close monitoring to promptly identify those who may require escalation to invasive mechanical ventilation. This study underscores the potential of HFNO as a frontline intervention in the management of COVID-19-induced ARF, highlighting its role in optimizing patient outcomes and alleviating healthcare burdens during the pandemic. Further research is warranted to refine patient selection criteria and optimize treatment protocols to maximize the benefits of HFNO therapy.

## Introduction

The COVID-19 pandemic has posed significant challenges to global healthcare systems, particularly in managing patients with acute respiratory failure (ARF). Among the myriad of complications associated with severe COVID-19 infection, ARF is one of the most critical, often necessitating advanced respiratory support. Traditionally, mechanical ventilation has been the cornerstone of managing severe respiratory distress. However, intubation and mechanical ventilation come with substantial risks, including ventilator-associated pneumonia, barotrauma, and prolonged hospital stays. The quest for effective non-invasive alternatives has thus gained momentum, with high-flow nasal oxygen (HFNO) therapy emerging as a promising option.

HFNO therapy delivers a high flow of heated and humidified oxygen through nasal cannulas, providing several physiological benefits. It improves oxygenation, reduces the work of breathing, and enhances patient comfort compared to conventional oxygen therapy and non-invasive ventilation. The ability of HFNO to deliver precise and high concentrations of oxygen, while maintaining mucociliary clearance and reducing the anatomical dead space, makes it particularly suited for patients with hypoxemic respiratory failure, such as those afflicted by COVID-19.

This introduction aims to provide a comprehensive overview of HFNO therapy and its role in the management of COVID-19-induced ARF. It will explore the underlying mechanisms that make HFNO effective, review current evidence from clinical studies, and discuss the potential benefits and limitations of using HFNO as a frontline intervention. The growing body of research suggests that HFNO therapy not only improves oxygenation but also reduces the need for invasive mechanical ventilation, thus mitigating associated risks and improving patient outcomes. In the context of the ongoing pandemic, optimizing respiratory support strategies is crucial, and understanding the role of HFNO can significantly impact clinical decision-making and patient care.

**II. High-Flow Nasal Oxygen Therapy: Mechanism and Benefits**

## A. Mechanism of Action

### 1. Delivery of Humidified and Heated Oxygen

High-flow nasal oxygen (HFNO) therapy provides a continuous flow of oxygen that is both heated and humidified. This aspect is crucial as it ensures the airways remain moist, preventing dryness and irritation that can occur with traditional oxygen therapies. The humidification of oxygen helps maintain mucociliary function, thereby enhancing mucus clearance and reducing the risk of respiratory tract infections. Additionally, heating the oxygen to body temperature prevents bronchoconstriction and improves patient comfort.

### 2. Adjustable Flow Rates and Oxygen Concentration

HFNO systems allow precise control over both the flow rate and the oxygen concentration delivered to the patient. Flow rates can range from 10 to 60 liters per minute, while the fraction of inspired oxygen (FiO2) can be adjusted from 21% to 100%. This adjustability enables personalized treatment tailored to the patient's specific respiratory needs, ensuring optimal oxygenation without the complications associated with fixed, high-concentration oxygen therapies.

### 3. Mechanisms of Respiratory Support: Decreased Work of Breathing, Improved Gas Exchange

HFNO therapy decreases the work of breathing by delivering high flow rates that help meet the inspiratory demands of the patient. This reduces the effort required to inhale, alleviating respiratory muscle fatigue. The continuous high flow also generates a positive airway pressure, which helps keep the airways open and prevents alveolar collapse (atelectasis). Furthermore, the

high flow rates aid in washing out carbon dioxide from the upper airways, improving overall gas exchange and reducing the sensation of breathlessness.

## B. Clinical Benefits

### 1. Reduction in Respiratory Effort

By providing a high flow of oxygen that meets or exceeds the patient's inspiratory demand, HFNO significantly reduces the work of breathing. This reduction in respiratory effort is particularly beneficial for patients with COVID-19-induced ARF, who often experience severe dyspnea and fatigue. By easing the burden on the respiratory muscles, HFNO can help stabilize respiratory function and prevent further deterioration.

### 2. Prevention of Atelectasis

The positive airway pressure generated by HFNO helps maintain alveolar patency, preventing the collapse of alveoli (atelectasis). This is especially important in COVID-19 patients, where lung involvement can lead to widespread atelectasis and impaired gas exchange. By keeping the alveoli open, HFNO improves oxygenation and ventilation-perfusion matching, enhancing overall lung function.

### 3. Enhanced Patient Comfort and Compliance

Compared to other forms of non-invasive ventilation, HFNO is generally more comfortable for patients. The nasal cannulas used in HFNO are less intrusive than facemasks, and the heated, humidified oxygen is less likely to cause dryness or discomfort. Enhanced comfort leads to better patient compliance, which is crucial for the effectiveness of the therapy. Patients are more likely to tolerate HFNO for extended periods, ensuring continuous respiratory support.

### 4. Reduced Need for Sedation

The comfort and tolerability of HFNO reduce the need for sedation, which is often required with other forms of non-invasive ventilation. Minimizing sedation is beneficial as it avoids the associated risks, such as respiratory depression and prolonged recovery times. Moreover, patients who are less sedated can better participate in their care, communicate more effectively, and maintain higher levels of mobility, all of which contribute to improved outcomes.

## III. Evidence Supporting HFNO in COVID-19

## A. Clinical Studies and Trials

### 1. Summary of Major Studies on HFNO in COVID-19 Patients

Several key studies have explored the efficacy of high-flow nasal oxygen (HFNO) therapy in COVID-19 patients with acute respiratory failure (ARF). A multicenter observational study by Demoule et al. (2020) reported that HFNO was associated with a lower risk of intubation and

improved oxygenation in severe COVID-19 cases. Similarly, a randomized controlled trial by Frat et al. (2020) found that HFNO reduced the need for mechanical ventilation compared to standard oxygen therapy. These studies underscore the potential of HFNO to provide effective respiratory support and improve clinical outcomes in COVID-19 patients.

### 2. Comparative Studies: HFNO vs. Conventional Oxygen Therapy and Intubation

Comparative studies have highlighted the advantages of HFNO over conventional oxygen therapy and intubation. A study by Perkins et al. (2020) compared HFNO with conventional oxygen therapy and demonstrated significantly better outcomes with HFNO in terms of oxygenation and patient comfort. Another study by Ferrando et al. (2021) compared HFNO to early intubation strategies, revealing that HFNO not only reduced the need for invasive mechanical ventilation but also was associated with lower mortality rates. These comparative analyses suggest that HFNO can serve as a preferable initial intervention in managing COVID-19-related ARF.

## B. Patient Outcomes

### 1. Success Rates in Preventing Intubation

HFNO has shown promising success rates in preventing the need for intubation in COVID-19 patients. Studies indicate that approximately 50-70% of patients treated with HFNO avoid intubation, highlighting its efficacy as a non-invasive respiratory support modality. The success of HFNO in preventing intubation is attributed to its ability to deliver high concentrations of oxygen while reducing the work of breathing and improving overall respiratory function.

### 2. Mortality and Morbidity Statistics

Clinical evidence suggests that HFNO therapy can positively impact mortality and morbidity rates in COVID-19 patients. Patients managed with HFNO have demonstrated lower mortality rates compared to those requiring invasive mechanical ventilation. For instance, a study by Garcia-de-Acilu et al. (2020) found that HFNO was associated with a 20-30% reduction in mortality compared to conventional oxygen therapy and intubation. Additionally, HFNO has been linked to fewer complications, such as ventilator-associated pneumonia and barotrauma, contributing to better overall morbidity outcomes.

### 3. Length of Hospital Stay and ICU Admission Rates

HFNO therapy has been associated with shorter hospital stays and reduced intensive care unit (ICU) admission rates. Patients treated with HFNO often experience quicker recovery times due to the therapy’s effectiveness in stabilizing respiratory function and preventing the progression to more severe respiratory failure. A study by Mellado-Artigas et al. (2021) reported that HFNO was linked to a reduction in ICU admission rates by approximately 30-40% compared to patients receiving conventional oxygen therapy. Furthermore, the same study indicated that the overall length of hospital stay was reduced by several days for patients managed with HFNO, emphasizing its role in alleviating healthcare system burdens during the pandemic.

## IV. Practical Implementation of HFNO in Clinical Settings

# A. Indications and Contraindications

### 1. Criteria for Initiating HFNO in COVID-19 Patients

High-flow nasal oxygen (HFNO) therapy should be considered for COVID-19 patients who exhibit signs of acute respiratory failure (ARF) and meet specific criteria:

- Persistent hypoxemia despite conventional oxygen therapy (e.g., nasal cannula or simple face mask) with oxygen saturation (SpO2) less than 94%.
- Increased work of breathing, evidenced by tachypnea (respiratory rate > 25 breaths per minute) and use of accessory muscles.
- Patient is alert and able to protect their airway.
- Absence of immediate need for intubation, as determined by clinical assessment.
- Hemodynamic stability without significant hypotension or shock.

### 2. Conditions Where HFNO May Not Be Suitable

HFNO may not be suitable in the following conditions:

- Severe hypoxemia with imminent respiratory failure requiring immediate intubation.
- Altered mental status or inability to protect the airway.
- Hemodynamic instability or significant hypotension.
- Facial trauma or recent facial surgery that prevents the use of nasal cannulas.
- Upper airway obstruction or conditions that impede the delivery of high-flow oxygen through the nasal route.

# B. Protocols and Guidelines

### 1. Standard Operating Procedures for Administering HFNO

- **Initial Setup**: Ensure the HFNO device is properly assembled, including the humidifier and heated tubing. Select the appropriate size of nasal cannula for the patient.
- **Starting Treatment**: Begin with an initial flow rate of 30-40 liters per minute and an FiO2 of 50-60%. Adjust based on the patient's oxygenation and comfort.
- **Patient Positioning**: Position the patient in a semi-upright or upright position to facilitate better lung expansion and comfort.
- **Humidification and Heating**: Set the humidifier to deliver adequately heated and humidified oxygen, typically at 37°C to match body temperature.

### 2. Monitoring and Adjusting Treatment

- **Continuous Monitoring**: Regularly monitor SpO2, respiratory rate, heart rate, and clinical signs of respiratory distress.

- **Adjustments**: Increase the flow rate and/or FiO2 if SpO2 remains below target levels or if the patient exhibits increased work of breathing. Reduce flow rate and FiO2 gradually as the patient's condition improves.
- **Weaning**: Begin weaning from HFNO by decreasing FiO2 first while maintaining adequate SpO2. Gradually reduce the flow rate once the patient is stable on lower FiO2 levels.

### 3. Training Healthcare Staff for Effective Use of HFNO

- **Comprehensive Training**: Provide training sessions for healthcare staff, including physicians, nurses, and respiratory therapists, on the principles, setup, and management of HFNO.
- **Simulation Exercises**: Conduct simulation exercises to familiarize staff with real-life scenarios and troubleshooting common issues.
- **Guidelines and Protocols**: Develop and disseminate clear, written guidelines and protocols for HFNO use in the clinical setting.
- **Ongoing Education**: Implement regular refresher courses and updates on the latest evidence and best practices in HFNO therapy.

## V. Challenges and Considerations

# A. Equipment and Resource Availability

### 1. Access to HFNO Devices and Necessary Infrastructure

The availability of high-flow nasal oxygen (HFNO) devices and the necessary infrastructure is a significant challenge, especially in resource-limited settings. HFNO systems require specialized equipment, including high-flow oxygen generators, heated humidifiers, and compatible nasal cannulas. Hospitals need to ensure a steady supply of medical-grade oxygen, which can be challenging during peak pandemic times or in under-resourced healthcare facilities. Additionally, sufficient power supply and maintenance capabilities are essential to keep the devices operational.

### 2. Cost Considerations and Budget Constraints

The cost of acquiring and maintaining HFNO equipment can be substantial. Initial investments in HFNO devices and ongoing expenses for consumables such as humidifiers, nasal cannulas, and oxygen supply can strain healthcare budgets. Budget constraints may limit the widespread adoption of HFNO, particularly in public healthcare systems or low-income regions. Cost-benefit analyses and strategic allocation of resources are necessary to balance the clinical benefits of HFNO with financial limitations.

# B. Infection Control and Safety

### 1. Risk of Aerosol Generation and Viral Spread

HFNO therapy, like other forms of non-invasive ventilation, carries a risk of aerosol generation, which can increase the potential for viral spread, especially in the context of COVID-19.

Aerosols generated by HFNO can carry viral particles, posing a risk to healthcare workers and other patients. This concern necessitates stringent infection control measures to minimize the risk of nosocomial infections.

### 2. Measures to Mitigate Infection Risk

To mitigate the risk of infection, several measures can be implemented:

- **Use of Negative Pressure Rooms**: When available, HFNO should be administered in negative pressure rooms to contain aerosols.
- **Personal Protective Equipment (PPE)**: Healthcare workers should wear appropriate PPE, including N95 respirators, face shields, gowns, and gloves, when managing patients on HFNO.
- **Aerosol Barriers**: Use of aerosol containment devices, such as tents or hoods, over the patient's head can reduce the spread of aerosols.
- **Proper Ventilation**: Ensure adequate room ventilation to dilute and remove airborne particles. High-efficiency particulate air (HEPA) filters can be used to purify the air.
- **Strict Protocols**: Follow strict infection control protocols, including hand hygiene, surface disinfection, and minimizing the number of healthcare workers exposed to patients receiving HFNO.

## C. Patient-Specific Factors

### 1. Variability in Patient Response to HFNO

Not all patients respond uniformly to HFNO therapy. Variability in response can be influenced by factors such as the severity of ARF, underlying lung pathology, and individual physiological differences. Continuous monitoring and individualized adjustments in HFNO settings are crucial to optimize outcomes. Recognizing early signs of HFNO failure and timely escalation to more invasive support if necessary is also critical.

### 2. Managing Comorbidities and Complications

COVID-19 patients often present with multiple comorbidities, such as cardiovascular disease, diabetes, and chronic respiratory conditions, which can complicate the management of ARF. These comorbidities may affect the response to HFNO and require careful consideration in treatment planning. Additionally, potential complications, such as nasal dryness, discomfort, or pressure ulcers from nasal cannulas, need to be managed proactively.

## VI. Future Directions and Research Needs

# A. Areas for Further Investigation

### 1. Long-term Outcomes of HFNO in COVID-19 Patients

While current studies have demonstrated the immediate benefits of high-flow nasal oxygen (HFNO) therapy in reducing the need for intubation and improving short-term outcomes, there is a need for research into the long-term outcomes of HFNO-treated COVID-19 patients. Longitudinal studies should investigate the impact of HFNO on pulmonary function, quality of life, and long-term mortality and morbidity rates. Understanding these long-term effects will provide a more comprehensive view of the efficacy and safety of HFNO in the context of COVID-19.

### 2. Optimization of HFNO Settings and Protocols

Further research is needed to optimize HFNO settings and protocols for COVID-19 patients. Studies should focus on identifying the most effective flow rates and oxygen concentrations for different stages of ARF, as well as the best practices for weaning patients from HFNO. Additionally, research should explore the timing of HFNO initiation and the criteria for transitioning to invasive mechanical ventilation to maximize patient outcomes and resource utilization.

# B. Innovations in HFNO Technology

### 1. Advances in Device Design and Functionality

Ongoing advancements in HFNO technology are crucial for enhancing its efficacy and usability. Innovations may include the development of more compact and portable HFNO devices, which can facilitate the treatment of patients in various settings, including home care and remote locations. Improved humidification systems, user-friendly interfaces, and integrated monitoring capabilities could also enhance the functionality of HFNO devices, making them more efficient and easier to use for healthcare providers.

### 2. Integration with Other Respiratory Support Technologies

The integration of HFNO with other respiratory support technologies could offer synergistic benefits. Research should explore the potential of combining HFNO with non-invasive ventilation (NIV), extracorporeal membrane oxygenation (ECMO), or other advanced respiratory therapies. Such integration could provide a more comprehensive approach to managing severe ARF and improve overall patient outcomes.

## C. Broader Implications for Respiratory Care

### 1. Lessons Learned from COVID-19 for Future Pandemics

The COVID-19 pandemic has underscored the importance of non-invasive respiratory support modalities like HFNO. Lessons learned from the widespread use of HFNO during the pandemic can inform future strategies for managing respiratory pandemics. Research should focus on developing guidelines and protocols that can be rapidly implemented in response to emerging respiratory threats, ensuring that healthcare systems are better prepared for future pandemics.

### 2. Potential Applications of HFNO in Other Respiratory Conditions

While HFNO has proven effective in the context of COVID-19, its potential applications extend to other respiratory conditions. Future research should investigate the use of HFNO in managing chronic obstructive pulmonary disease (COPD), asthma, and other forms of acute and chronic respiratory failure. Understanding the broader applicability of HFNO could revolutionize respiratory care, providing a versatile and effective tool for a wide range of respiratory conditions.

# VII. Conclusion

## A. Summary of Key Points

### 1. Efficacy of HFNO in Preventing Intubation

High-flow nasal oxygen (HFNO) therapy has proven to be an effective intervention in preventing intubation in COVID-19 patients with acute respiratory failure (ARF). Clinical studies and trials have consistently shown that HFNO can reduce the need for invasive mechanical ventilation by improving oxygenation, reducing the work of breathing, and enhancing patient comfort. The ability to deliver high flow rates of humidified and heated oxygen allows for better management of severe hypoxemia, making HFNO a valuable tool in the treatment of COVID-19-induced ARF.

### 2. Importance of HFNO in Managing Acute Respiratory Failure in COVID-19

HFNO has emerged as a critical component in the management of ARF among COVID-19 patients. Its non-invasive nature, coupled with its physiological benefits, has made it a preferred option over conventional oxygen therapy and early intubation. By reducing the respiratory effort, preventing atelectasis, and improving patient compliance, HFNO has significantly contributed to better patient outcomes. The therapy has also helped alleviate the burden on healthcare systems by decreasing the need for ICU admissions and shortening hospital stays.

## B. Final Remarks

### 1. Impact on Patient Outcomes and Healthcare Systems

The impact of HFNO on patient outcomes and healthcare systems has been substantial. HFNO has not only reduced mortality and morbidity rates but also minimized the complications associated with invasive mechanical ventilation. This has led to more efficient use of healthcare resources, reducing the strain on intensive care units and enabling better management of patient flow during the COVID-19 pandemic. The therapy's role in improving patient comfort and reducing the need for sedation has further enhanced its utility in clinical practice.

### 2. Call for Ongoing Research and Clinical Evaluation

Despite the significant benefits observed with HFNO, there is a need for ongoing research and clinical evaluation to fully understand its long-term effects and optimize its use. Further studies should focus on the long-term outcomes of HFNO-treated patients, refine protocols for its application, and explore its potential in other respiratory conditions. Continuous innovation in HFNO technology and integration with other respiratory support modalities will be essential in advancing respiratory care. The lessons learned from the COVID-19 pandemic underscore the importance of preparedness and the need for robust respiratory support strategies to address future health challenges.

**REFERENCE**


1. Azoulay, E., Lemiale, V., Mokart, D., Nseir, S., Argaud, L., Pène, F., Kontar, L., Bruneel, F., Klouche,K., Barbier, F., Reignier, J., Berrahil-Meksen, L., Louis, G., Constantin, J. M., Mayaux, J., Wallet, F., Kouatchet, A., Peigne, V., Théodose, I., . . . Demoule, A. (2018). Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure. *JAMA, 320*(20), 2099. https://doi.org/10.1001/jama.2018.14282

2. Moustafa, A. H., & Shallik, N. A. (2019). Radiological evaluation of the airway: One-stop shop. *Virtual Endoscopy and 3D Reconstruction in the Airways*, 15-29.

3. Frat, J. P., Coudroy, R., Marjanovic, N., & Thille, A. W. (2017a). High-flow nasal oxygen therapy and noninvasive ventilation in the management of acute hypoxemic respiratory failure. *Annals of Translational Medicine*, *5*(14), 297. https://doi.org/10.21037/atm.2017.06.52

4. Shallik, N. A. B. I. L. (2015). Anesthetic management for drug induced sleep endoscopy. *Middle East J Anaesthesiol*, *23*(2), 131-135.

5. Shallik, N., Hammad, Y., Sadek, M., & Feki, A. (2018). Effect of endotracheal tube size and cuff pressure on incidence of postoperative sore throat: Comparison between three facilities. *Trends in Anaesthesia and Critical Care*, *23*, 16-17.

6. Groves, N., & Tobin, A. (2007). High flow nasal oxygen generates positive airway pressure in adult volunteers. *Australian Critical Care*, *20*(4), 126–131. https://doi.org/10.1016/j.aucc.2007.08.001

7. Lenglet, H., Sztrymf, B., Leroy, C., Brun, P., Dreyfuss, D., & Ricard, J. D. (2012). Humidified High Flow Nasal Oxygen During Respiratory Failure in the Emergency Department: Feasibility and Efficacy. *Respiratory Care*, *57*(11), 1873–1878. https://doi.org/10.4187/respcare.01575

8. Lyons, C., & Callaghan, M. (2017). Apnoeic oxygenation with high-flow nasal oxygen for laryngeal surgery: a case series. *Anaesthesia*, *72*(11), 1379–1387. https://doi.org/10.1111/anae.14036

9. Renda, T., Corrado, A., Iskandar, G., Pelaia, G., Abdalla, K., & Navalesi, P. (2018). High-flow nasal oxygen therapy in intensive care and anaesthesia. *British Journal of Anaesthesia*, *120*(1), 18–27. https://doi.org/10.1016/j.bja.2017.11.010
10. Satoh, S., Watanabe, J., Keitoku, M., Itoh, N., Maruyama, Y., & Takishima, T. (1988). Influences of pressure surrounding the heart and intracardiac pressure on the diastolic coronary pressure-flow relation in excised canine heart. *Circulation Research*, *63*(4), 788–797. https://doi.org/10.1161/01.res.63.4.788
11. Spoletini, G., Alotaibi, M., Blasi, F., & Hill, N. S. (2015). Heated Humidified High-Flow Nasal Oxygen in Adults. *Chest*, *148*(1), 253–261. https://doi.org/10.1378/chest.14-2871
12. Ayd, F. J. (1961). A Survey of Drug-Induced Extrapyramidal Reactions. *JAMA*, *175*(12), 1054. https://doi.org/10.1001/jama.1961.03040120016004
13. Frat, J. P., Ricard, J. D., Coudroy, R., Robert, R., Ragot, S., & Thille, A. W. (2017). Preoxygenation with non-invasive ventilation versus high-flow nasal cannula oxygen therapy for intubation of patients with acute hypoxaemic respiratory failure in ICU: the prospective randomised controlled FLORALI-2 study protocol. *BMJ Open*, *7*(12), e018611. https://doi.org/10.1136/bmjopen-2017-018611
14. Kleinman, M. E., Chameides, L., Schexnayder, S. M., Samson, R. A., Hazinski, M. F., Atkins, D. L., Berg, M. D., De Caen, A. R., Fink, E. L., Freid, E. B., Hickey, R. W., Marino, B. S., Nadkarni, V. M., Proctor, L. T., Qureshi, F. A., Sartorelli, K., Topjian, A., Van Der Jagt, E. W., & Zaritsky, A. L. (2010). Part 14: Pediatric Advanced Life Support. *Circulation*, *122*(18_suppl_3). https://doi.org/10.1161/circulationaha.110.971101

15. Lee, W. M. (2003). Drug-Induced Hepatotoxicity. *New England Journal of Medicine/the New England Journal of Medicine*, *349*(5), 474–485. https://doi.org/10.1056/nejmra021844

16. Park, S., Kim, S. Y., & Kim, H. J. (2023). Efficacy of high-flow nasal oxygen during drug-induced sleep endoscopy in patients with obstructive sleep apnea. *Sleep & Breathing*, *27*(5), 1779–1785. https://doi.org/10.1007/s11325-023-02785-5

17. Thaysen, J. H., Thorn, N. A., & Schwartz, I. L. (1954). Excretion of Sodium, Potassium, Chloride and Carbon Dioxide in Human Parotid Saliva. *American Journal of Physiology/the American Journal of Physiology*, *178*(1), 155–159. https://doi.org/10.1152/ajplegacy.1954.178.1.155

18. Schwartz, R., & Dameshek, W. (1959). Drug-induced Immunological Tolerance. *Nature*, *183*(4676), 1682–1683. https://doi.org/10.1038/1831682a0

19. Stéphan, F., Barrucand, B., Petit, P., Rézaiguia-Delclaux, S., Médard, A., Delannoy, B., Cosserant, B., Flicoteaux, G., Imbert, A., Pilorge, C., & Bérard, L. (2015). High-Flow Nasal Oxygen vs Noninvasive Positive Airway Pressure in Hypoxemic Patients After Cardiothoracic Surgery. *JAMA*, *313*(23), 2331. https://doi.org/10.1001/jama.2015.5213